TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Meribel Pharma Höganäs AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
112,934
|
125,781
|
108,884 |
| Financial expenses |
2,957
|
5,752
|
5,453 |
| Earnings before taxes |
-26,100
|
-10,822
|
-15,456 |
| EBITDA |
-18,986
|
-1,384
|
-7,630 |
| Total assets |
120,033
|
119,754
|
80,269 |
| Current assets |
98,157
|
94,598
|
49,406 |
| Current liabilities |
31,016
|
106,830
|
74,969 |
| Equity capital |
89,018
|
12,923
|
5,300 |
| - share capital |
65
|
67
|
67 |
| Employees (average) |
89
|
91
|
103 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
74.2%
|
10.8%
|
6.6% |
| Turnover per employee |
1,269
|
1,382
|
1,057 |
| Profit as a percentage of turnover |
-23.1%
|
-8.6%
|
-14.2% |
| Return on assets (ROA) |
-19.3%
|
-4.2%
|
-12.5% |
| Current ratio |
316.5%
|
88.6%
|
65.9% |
| Return on equity (ROE) |
-29.3%
|
-83.7%
|
-291.6% |
| Change turnover |
-8,687
|
16,336
|
26,185 |
| Change turnover % |
-7%
|
15%
|
32% |
| Chg. No. of employees |
-2
|
-12
|
-3 |
| Chg. No. of employees % |
-2%
|
-12%
|
-3% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.